Latest News

STAT Plus: Argenx antibody drug improves symptoms in patients with myasthenia gravis

Argenx, a Belgian drug maker, said Tuesday that its experimental medicine improved the symptoms of patients with a rare neuromuscular disease, achieving the primary goal of a late-stage clinical trial.

The positive study results will enable Argenx to seek U.S. approval before the end of the year as a potentially new treatment for patients with generalized myasthenia gravis, a chronic and debilitating condition in which the body’s own antibodies disrupt the communication between nerve endings and muscles.

Continue to STAT Plus to read the full story…

Source link

Related posts

What are the risks of #AI in #healthcare? #digitalhealth #ticktohealth…


U.S. is ‘less safe’ from coronavirus when CDC goes quiet, former director says


Methods for Exploring Simulation Models


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World